SP3/SP4 Antibody

Shipped with Ice Packs
In Stock

Description

Introduction

SP3 and SP4 are transcription factors belonging to the Sp/Krüppel-like family (KLF), involved in regulating gene expression by binding to GC-box motifs in DNA promoters. These proteins play critical roles in cellular processes such as proliferation, apoptosis, and tumor progression. Antibodies targeting SP3 and SP4 are essential tools for studying their functions, diagnostics, and therapeutic targeting. This article synthesizes data from proteomics, oncology, and immunology to provide a comprehensive overview of SP3/SP4 antibodies.

Biological Roles of SP3 and SP4

  • SP3: Functions as a transcriptional activator or repressor depending on isoform and post-translational modifications (e.g., sumoylation, acetylation) . It is ubiquitously expressed across tissues and regulates oncogenic factors like VEGF and EGFR .

  • SP4: Promotes tumor progression by activating pathways such as Wnt/β-catenin via PHF14 transcription . High SP4 expression correlates with poor prognosis in esophageal squamous cell carcinoma (ESCC) .

Oncology

  • ESCC: SP4 overexpression promotes tumor growth by activating PHF14 and the Wnt/β-catenin pathway . SP4 inhibition suppresses proliferation and induces apoptosis .

  • DM: Coexistence of anti-SP4 and anti-TIF1γ autoantibodies in DM patients is associated with a 0% cancer incidence vs. 31% in TIF1γ-only patients (p=0.001) .

Proteomics

  • SP4-based methods (SP4-GB) enhance recovery of hydrophobic and transmembrane proteins, improving deep proteome profiling .

Future Directions

  • Therapeutic Targeting: SP4 inhibition may offer a strategy for ESCC treatment .

  • Biomarkers: Anti-SP4 autoantibodies could serve as prognostic markers in DM .

  • Method Development: Optimizing SP4-based workflows for low-concentration protein samples remains a challenge .

Product Specs

Form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Lead Time
Typically, we can ship the products within 1-3 business days after receiving your order. Delivery times may vary depending on the purchase method or location. Please consult your local distributors for specific delivery timelines.
Synonyms
D130027J01Rik antibody; DKFZp686O1631 antibody; GC binding transcription factor Sp 3 antibody; GC binding transcription factor Sp3 antibody; MGC105187 antibody; OTTMUSP00000014207 antibody; SP 3 antibody; Sp 3 transcription factor antibody; SP3 antibody; Sp3 transcription factor antibody; SP3_HUMAN antibody; Specificity protein 3 antibody; SPR 2 antibody; SPR-2 antibody; SPR2 antibody; Transcription factor SP 3 antibody; Transcription factor Sp3 antibody
Target Names
SP3/SP4
Uniprot No.

Target Background

Function
SP3/SP4 is a transcription factor that can act as an activator or repressor depending on its isoform and/or post-translational modifications. It binds to GT and GC boxes in promoter elements and competes with SP1 for the GC-box promoters. While it is a weak activator of transcription, it can activate a number of genes involved in various cellular processes such as cell cycle regulation, hormone induction, and housekeeping functions.
Gene References Into Functions
  1. Knockdown of SP3 in cells with non-risk alleles has shown an upregulation in the expression of the nearby cyclin-dependent kinase inhibitor 1C (CDKN1C) gene. This suggests that CDKN1C is potentially one of the functional targets of SNP rs163184, which modulates the binding activity of the locus for Sp3 and Lsd1/Kdm1a. PMID: 29207083
  2. Elevated SP3 expression has been associated with hepatocellular carcinoma. PMID: 28844709
  3. A new regulatory model of COL1A1 regulation by HIF-1 has been established, highlighting its relationship with the Sp3 transcription factor. These findings provide insights into the mechanisms controlling COL1A1 gene expression. PMID: 27521280
  4. Evidence indicates that the antitumor activity of trefoil factor 2 (TFF2) is mediated by an interaction with the transcription factor Sp3 in gastric cancer cells. PMID: 27668303
  5. Studies have demonstrated that a 186bp region is the minimal essential region for KLF5 expression and that Sp3-GC1 binding is crucial for its basal expression. PMID: 27940107
  6. Sp3 has been identified as a major regulator of BNIP3 in prostate cancer. PMID: 26012884
  7. Chromosome 2q31.1 is located between the genes encoding for Sp3 transcription factor, which regulates the expression of genes linked to glomerular function and the pathogenesis of nephropathy, and the CDCA7 transcription factor. PMID: 24029427
  8. SP3 interacts with the TNIP1 promoter and contributes to its basal and inducible expression. PMID: 23464785
  9. Findings suggest a role for transcription factor Sp3 in sarcomas as a driver for the expression of the metastasis-related gene AFAP1L1 (actin filament-associated protein 1-like 1). PMID: 23326307
  10. The transcription factor Sp3 acts to reduce the expression of many genes with Sp3 binding sites in their promoters by inhibiting the transition of paused RNA PolII to productive elongation. PMID: 23401853
  11. Transcriptional control of the multi-drug transporter ABCB1 by transcription factor Sp3 has been observed in different human tissues. PMID: 23133566
  12. AP-1 and Sp3 are key regulators of IL-1beta-mediated modulation of xylosyltransferase I expression. PMID: 23223231
  13. This study indicated that Sp3 is a major regulator of TFF2 expression. PMID: 23000412
  14. Sp1 or Sp3 siRNA knockdown reduced 1alpha,25-dihydroxyvitamin D3-regulated hCYP24A1 promoter activity. PMID: 22871965
  15. Extracellular signal-regulated kinase mitogen-activated protein kinase-dependent SOCS-3 gene induction requires c-Jun, signal transducer and activator of transcription 3, and specificity protein 3 transcription factors. PMID: 22311708
  16. The two factors Klf4 and Sp3 exert an overlapping repressor function through their binding to the Notch1 promoter. PMID: 20442780
  17. Results suggest that Sp3 plays a key role in the expression of NOX4 in various cell lineages in humans. PMID: 21235713
  18. Transcription of the transforming growth factor beta activating integrin beta8 subunit is regulated by SP3, AP-1, and the p38 pathway. PMID: 20519498
  19. The human proximal FOXP3 promoter is controlled by activation through the TCR involving PKC and the NF-kappaB subunit p65 and by inhibition through a negative feedback loop and SP3. PMID: 20462637
  20. Sp3-mediated transcriptional repression is due, at least in part, to competition for promoter-specific transcription factors. PMID: 11773047
  21. Results indicate that Sp1 and Sp3 associate with the hTERT promoter, recruiting HDAC for the localized deacetylation of nucleosomal histones and transcriptional silencing of the hTERT gene in normal human somatic cells. PMID: 12151407
  22. CK2 phosphorylation of HDAC2 recruited by Sp1 or Sp3 could regulate HDAC activity and alter the balance of histone deacetylase and histone acetyltransferase activities, leading to dynamic chromatin remodeling of estrogen-regulated genes. PMID: 12176973
  23. This protein plays a role in the identification of regulatory elements in the human adipose most abundant gene transcript-1(apM-1) promoter. PMID: 12378384
  24. The 5' UTR of Sp3 transcription factor has been characterized. PMID: 12411611
  25. This protein and Sp1 are involved in the upregulation of human deoxyribonuclease II transcription during differentiation of HL-60 cells. PMID: 12694199
  26. Acetylation acts as a switch that controls the repressor and activator role of Sp3. PMID: 12837748
  27. TFIIB interacts with SP1/SP3 at the SP1 site. PMID: 12972613
  28. Evidence suggests that AML-1, PU.1, and Sp3 cooperatively and directly mediate BPI-expression during myeloid differentiation. PMID: 14623259
  29. SP3 acts as a positive regulator on the core promoter of the human ZPK gene. PMID: 14697235
  30. S-nitrosoglutathione increases Sp3 binding to DNA and transcription of CFTR at physiological concentrations, but inhibits Sp3 binding and CFTR transcription at nitrosative stress levels. PMID: 14766015
  31. An SP3 binding site in the IGFBP4 gene has been identified, and the role of SP3 in regulating its promoter activity in CaCo-2 cells has been studied. PMID: 14767471
  32. Sp3 isoform ratios and activity are controlled at the translational level, which regulates the expression of genes during mitosis and has effects on cell cycle regulation and tumorigenesis. PMID: 14767558
  33. Sp3 binding is regulated by methylation in the core-promoter region of the chondromodulin-I gene. PMID: 15107420
  34. Four isoforms are derived from alternative translational start sites at positions 1, 37, 856, and 907; the transcriptional activity of all the Sp3 isoforms is regulated by SUMO modification. PMID: 15247228
  35. Sp3 isoforms are sumoylated in vivo, and this post-translational modification plays a significant role in the regulation of Sp3-mediated transcription. PMID: 15494207
  36. SP3 protein negatively regulates beta myosin heavy chain gene expression during skeletal muscle inactivity. PMID: 15572681
  37. Ten genes were down-regulated following treatment of the T-ALL cells with 0.15 and 1.5 microg/mL of metal ores at 72 h. DNA-binding transcriptional activator activity. PMID: 15747776
  38. Sp3 is a strong activator of dopamine transporter transcriptional activity. PMID: 15816870
  39. Cytochrome b5 gene transcription is regulated by Sp3, GATA-6, and steroidogenic factor 1 in human adrenal NCI-H295A cells. PMID: 15831526
  40. Results indicate a significant role for Sp1, Sp3, and NF-Y in the transcriptional regulation of the Sp3 proximal promoter. PMID: 16024108
  41. The Sp3 D-domain modulates its protein levels and activation of the p21(CIP1/WAF1) promoter. PMID: 16081043
  42. Increased pAPCP promoter activity in the MCF10A cell line in response to DMBA treatment is mediated by Sp3. PMID: 16150893
  43. Sp3 and Sp4 cooperatively interact with ERalpha to activate VEGFR2. PMID: 16574784
  44. PADI3 expression is driven by Sp3 binding to the promoter region. PMID: 16671893
  45. Sp3 and Sp1 transcription factors play a crucial role in the expression of the Protein S gene. PMID: 16672217
  46. Sp3 binds to the gamma-ENaC promoter, and Sp3 binding is enhanced by butyrate. PMID: 17241874
  47. Data show that increased generation of C18-ceramide by hCerS1 expression mediates the association and recruitment of deacetylated Sp3/HDAC1 to the hTERT promoter, resulting in local histone H3 deacetylation and repression of the promoter. PMID: 17548428
  48. IL-1beta decreases type II TGFbeta receptor expression by inducing Sp3 via NFkappaB. PMID: 18053089
  49. Results show activation of the Sp3 proximal promoter upon overexpression of NF-1, c-Myb, B-Myb, c-Jun, and c-Fos, and repression after overexpression of E2F/DP1. PMID: 18342022
  50. Observations suggest that deficient expression of the SP3 gene occurs in Chinese MS patients, and that SP3 expression may correlate with the clinical manifestations of MS and play roles in its immunological pathogenesis. PMID: 18393243

Show More

Hide All

Database Links

HGNC: 11208

OMIM: 601804

KEGG: hsa:6670

STRING: 9606.ENSP00000310301

UniGene: Hs.531587

Protein Families
Sp1 C2H2-type zinc-finger protein family
Subcellular Location
Nucleus. Nucleus, PML body. Note=Localizes to the nuclear periphery and in nuclear dots when sumoylated. Some localization in PML nuclear bodies.
Tissue Specificity
Ubiquitously expressed.

Q&A

What are SP3 and SP4 techniques and how do they differ?

SP3 (Single-pot, solid-phase-enhanced sample preparation) is a protein cleanup technique that uses organic solvent and magnetic beads to denature and capture protein aggregates, followed by wash steps to remove contaminants. SP4 (Solvent precipitation SP3) is an alternative that captures acetonitrile-induced protein aggregates by brief centrifugation rather than magnetism, with optional low-cost inert glass beads to simplify handling. The key difference is the mechanism of protein capture: SP3 relies on magnetic bead interaction while SP4 uses centrifugation to pellet precipitated proteins .

What are the primary advantages of SP4 over SP3 for protein recovery?

SP4 demonstrates superior recovery for higher protein inputs (1-5000 μg preparations) and improved reproducibility (median protein R² 0.99 for SP4 vs. 0.97 for SP3). Additionally, deep proteome profiling shows that SP4 yields greater recovery of low-solubility and transmembrane proteins compared to SP3. SP4 offers cost-effective input scalability and the option to omit beads entirely while retaining the speed and compatibility advantages of SP3 .

When should researchers choose SP3 versus SP4 for their proteomics experiments?

Researchers should select SP3 for low-concentration samples, as it provides superior recovery in these conditions. For higher protein concentrations, SP4 is preferable as it recovers equivalent or greater protein yields with better reproducibility. When working with samples containing high proportions of membrane or hydrophobic proteins, SP4 is the recommended method as it provides significantly better recovery of these protein classes .

What are the optimal organic solvent concentrations for SP3 and SP4?

Research indicates benefits to aggregating protein using 80% versus 50% organic solvent for both SP3 and SP4. In comparative studies, using 50% ACN with SP3 resulted in losses of low-molecular-weight and soluble proteins (p < 0.0001) compared to 80% ACN. The differences in protein recovery were more pronounced when comparing SP4 with 80% ACN to SP3 with 50% ACN. Careful optimization of organic solvent concentration is crucial to maximize protein recovery, particularly for challenging protein types .

How does detergent-assisted digestion affect protein recovery in SP3 and SP4?

Sodium deoxycholate (SDC)-assisted digestion can combat the insolubility of protein pellets generated by SP4 and increase the detection of hydrophobic proteins in both SP3 and SP4 protocols. This approach is particularly valuable when analyzing samples containing high proportions of membrane proteins or other hydrophobic proteins that might otherwise be under-represented in the final analysis .

What are the functional roles of Sp3 and Sp4 transcription factors in cancer cells?

Sp3 and Sp4 are specificity protein transcription factors that exhibit pro-oncogenic activity similar to the more extensively studied Sp1. Individual knockdown of Sp3 and Sp4 in various cancer cell lines (including breast, lung, colon, kidney, and pancreatic) results in inhibition of cell growth, decreased survival, and inhibition of migration/invasion. This demonstrates that both Sp3 and Sp4 significantly contribute to cancer cell progression. In vivo studies using athymic nude mouse xenograft models show that loss of these transcription factors significantly inhibits tumor growth and reduces tumor weights .

What is the relationship between Sp1, Sp3, and Sp4 expression?

Complex autoregulation exists among Sp1, Sp3, and Sp4 transcription factors. Studies across multiple cancer cell lines have shown that knockdown of one Sp factor can affect the expression of others. For example, siSp3 decreased expression of Sp1 in SKBR3, SW480, and A549 cells and decreased Sp4 in L3.6pL and MiaPaCa2 cells. Similarly, siSp4 decreased Sp1 in several cell lines and Sp3 in others. This interregulation varies by cell line, with Panc1 cells showing the most specific knockdown with minimal effects on other Sp proteins .

Why are Sp3 and Sp4 considered potential therapeutic targets?

Sp1, Sp3, and Sp4 are classified as non-oncogene addiction (NOA) genes, making them attractive drug targets for individual and combined cancer chemotherapies. Their knockdown significantly inhibits cancer progression through multiple mechanisms, including decreased cell proliferation, increased apoptosis, and reduced migration/invasion capabilities. These transcription factors regulate several pro-oncogenic factors including vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), survivin, and bcl2, making them central nodes in cancer signaling networks .

How can researchers validate and compare SP3 and SP4 techniques in their laboratories?

To properly validate these techniques, researchers should perform side-by-side comparisons with standardized samples across multiple protein concentrations (1-5000 μg). Assessment criteria should include: 1) total protein yield, 2) number of unique peptides and proteins identified, 3) reproducibility metrics (R² values and CV%), and 4) recovery of specific protein classes (particularly membrane and low-solubility proteins). For rigorous validation, researchers should analyze physical and chemical properties of recovered proteins, including hydrophobicity, molecular weight distribution, and solubility characteristics. Multi-laboratory validation with diverse sample types is recommended to confirm consistent performance .

What statistical approaches are recommended for comparing SP3 and SP4 performance?

For robust statistical comparison, at least three sample-preparation replicates should be prepared for each clean-up technique, with three technical instrument replicates per sample. Statistical significance for pairwise comparisons (SP3 versus SP4, SP3 versus SP3(DA), and SP4 versus SP4(DA)) should be determined by two-tailed F-tests. When analyzing differential protein recovery, researchers should use criteria such as log₂(FC) > 0.5 with p < 0.05 to identify proteins with significantly different recovery between methods .

How should researchers optimize SP4 for different subcellular fractions?

Optimization should be tailored to specific subcellular fractions based on their protein composition. For membranous fractions rich in hydrophobic proteins, SP4 with 80% organic solvent is recommended. For fractions containing mostly hydrophilic proteins (cytoplasmic, soluble-nuclear), SP3 might provide better coverage. Researchers should consider employing detergent-assisted digestion protocols particularly for membrane-rich fractions to combat protein pellet insolubility. Experimental design should include appropriate controls and multiple subcellular fractions (whole-cell lysate, cytoplasmic, membranous, soluble-nuclear, chromatin-bound-nuclear, and cytoskeletal) to comprehensively evaluate method performance .

When might researchers benefit from combining SP3 and SP4 approaches?

An integrated approach combining both SP3 and SP4 might be beneficial for achieving comprehensive proteome coverage. SP3 demonstrates superior performance for low-concentration samples and may better capture hydrophilic proteins through its dual HILIC-like and protein-aggregation mechanisms. Conversely, SP4 exhibits advantages for higher protein concentrations and improved recovery of hydrophobic, membrane-associated proteins. A sequential or parallel workflow incorporating both methods could maximize proteome coverage, particularly for complex samples with diverse protein types .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.